<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Neurology</journal-id>
<journal-id journal-id-type="iso-abbrev">Neurology</journal-id>
<journal-id journal-id-type="hwp">neurology</journal-id>
<journal-id journal-id-type="publisher-id">neur</journal-id>
<journal-id journal-id-type="pmc">neurology</journal-id>
<journal-id journal-id-type="publisher-id">NEUROLOGY</journal-id>
<journal-title-group>
<journal-title>Neurology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0028-3878</issn>
<issn pub-type="epub">1526-632X</issn>
<publisher>
<publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>
<publisher-loc>Hagerstown, MD</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30541864</article-id>
<article-id pub-id-type="pmc">6340340</article-id>
<article-id pub-id-type="publisher-id">NEUROLOGY2018890111</article-id>
<article-id pub-id-type="doi">10.1212/WNL.0000000000006729</article-id>
<article-categories>
<subj-group subj-group-type="hwp-journal-coll">
<subject>64</subject>
<subject>76</subject>
<subject>91</subject>
<subject>228</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title><italic>SYNGAP1</italic> encephalopathy</article-title>
<subtitle>A distinctive generalized developmental and epileptic encephalopathy</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Vlaskamp</surname>
<given-names>Danique R.M.</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shaw</surname>
<given-names>Benjamin J.</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Burgess</surname>
<given-names>Rosemary</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mei</surname>
<given-names>Davide</given-names>
</name>
<degrees>MSc</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for travel or speaker honoraria:</title>
<list-item>
<p>1) BioMarin Pharmaceutical, Funding for travel &amp; Honoraria for speaking engagements</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>(1) Epilepsia, Editorial Board, 2011-2017</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Montomoli</surname>
<given-names>Martino</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xie</surname>
<given-names>Han</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>National Natural Science Foundation of China (Grant No. 81501123)</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Myers</surname>
<given-names>Candace T.</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bennett</surname>
<given-names>Mark F.</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>XiangWei</surname>
<given-names>Wenshu</given-names>
</name>
<degrees>BSc</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Williams</surname>
<given-names>Danielle</given-names>
</name>
<degrees>BappSc</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>(1)AIA Australia, Snr Manager Corporate Solutions, 6 years</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Maas</surname>
<given-names>Saskia M.</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Brooks</surname>
<given-names>Alice S.</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mancini</surname>
<given-names>Grazia M.S.</given-names>
</name>
<degrees>MD, PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>van de Laar</surname>
<given-names>Ingrid M.B.H.</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>Erasmus MC, University Medical Center Rotterdam: Erasmus University Rotterdam Fellowship 2016-2019, principal investigator</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>Dutch Heart Foundation, grant number 2014T007, principal investigator, 2014-2018</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>van Hagen</surname>
<given-names>Johanna M.</given-names>
</name>
<degrees>MD, PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ware</surname>
<given-names>Tyson L.</given-names>
</name>
<degrees>FRACP</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Webster</surname>
<given-names>Richard I.</given-names>
</name>
<degrees>MBBS, MSc, FRACP</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for travel or speaker honoraria:</title>
<list-item>
<p>Speaker Honoraria Commercial entity Australian Medical Forum GP Update</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>Associate Editor Neurology Journal of Paediatrics and Child Health 2016 ongoing</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Malone</surname>
<given-names>Stephen</given-names>
</name>
<degrees>FRACP</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>1. UCB Pharma 2. Biomarin</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for travel or speaker honoraria:</title>
<list-item>
<p>1. UCB Pharma, funding for travel and speaker honoraria 2. Biomarin, funding for travel and honoraria</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>UCB Pharma</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Berkovic</surname>
<given-names>Samuel F.</given-names>
</name>
<degrees>MD, FRS</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>UCB Pharma Eisai, Australia</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>Brain (Editorial Board ? 2000 - 2004; Advisory Board 2005-2016 ) Epileptic Disorders (1999- ) Lancet Neurology (2011- )</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>I am one of the inventors listed on a patent held by Bionomics Inc on diagnostic testing of using the SCN1A gene. International publication number WO2006/133508; filed 16/06/2006. I am one of the inventors on pending patent WO61/010176: Therapeutic Compound that relates to discovery of PCDH19 gene as the cause of familial epilepsy with mental retardation limited to females</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>UCB unrestricted research grant SciGen unrestricted research grant Eisai unrestricted research grant</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>National Health and Medical Research Council of Australia (Program Grant #1091593; 2016-2020) NINDS (U01 NS077367-01; 2011-2014)</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kalnins</surname>
<given-names>Renate M.</given-names>
</name>
<degrees>MBBS</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sicca</surname>
<given-names>Federico</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>Molecular &amp; Cellular Epilepsy, Editorial board member, 2014-2016</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>Italian Ministry of Health, Current research, PI, 2014- 2018 Italian Ministry of Health, Targeted research, Site Investigator, 2014-2016</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>Telethon Foundation Italy, grant GGP11188, PI, 2011-2016</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Korenke</surname>
<given-names>G. Christoph</given-names>
</name>
<degrees>MD, PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>van Ravenswaaij-Arts</surname>
<given-names>Conny M.A.</given-names>
</name>
<degrees>MD, PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>European Journal of Medical Genetics, member of editorial board, since 2005</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hildebrand</surname>
<given-names>Michael S.</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>(1) National Health and Medical Research Council Project Grant 1079058 (2014-2017) (2) National Health and Medical Research Council Career Development Fellowship 1063799 (2014-2018)</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mefford</surname>
<given-names>Heather C.</given-names>
</name>
<degrees>MD, PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>(1) Professional Advisory Board, Lennox Gastaut Foundation (2) Scientific &amp; Genetics Advisory Board, Simons SPARK study (3) Scientific Advisory Board, Dravet Syndrome Foundation</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>(1) Science Translational Medicine, Associate Scientific Editor 2014-1015 (2) Epilepsy Currents, Clinical Science Editor 2015-present (3) GeneReviews, Molecular Editor, 2016-2017 (4) Human Molecular Genetics Editorial Board, 2017 - present</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>1. NIH/NINDS Grant NS069605 2. NIH/NINDS Grant NS068605 3. NIH/NINDS Grant NS077303 4. NIH/NINDS Grant NS077364 5. NIH/NINDS Grant NS077275 6. NIH/NICHD Grant HD000836</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jiang</surname>
<given-names>Yuwu</given-names>
</name>
<degrees>MD, PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Guerrini</surname>
<given-names>Renzo</given-names>
</name>
<degrees>MD, FRCP</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>Honoraria for Advisory Board activities and travel related expenses for: (1) Eisai Inc, (2) Novartis, (3) Zogenix, (4) Biomarin, (5) UCB, GW Pharma.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for travel or speaker honoraria:</title>
<list-item>
<p>(1) EISAI: funding for travel. (2) Novartis funding for travel; (3) UCB: Funding for travel. (3) Biomarin funding for travel, (4) Novartis funding for travel, (5) GW funding for travel</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>(1) Epilepsia: Associate Editor 2006-2013, (2) Progress in Epileptic Disorders, International Advisory Board, 2007- (3) Neuropediatrics, Editorial Board, 2001-2009 (4) Journal of Child Neurology, Editorial Board, 1995-2010, (5) Seizure, Editorial Board 2005-, (6) BMC Medical Genetics,Editorial Board, 2006-, (7) Topics in Epilepsy, Editorial Board, 2009- (8) Journal of Pediatric Epilepsy, Editorial Board, 2011- (9) Epileptic Disorders,Editorial Board, 1999-2012 (10) European Neurological Journal, Editorial Board, 2010- (11) Neurology, Editorial Board, 2013- (12) Journal of Embryology &amp; Developmental Biology, 2016-</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>(1) Epilepsy and Movements disorders, Cambridge University Press, 2002, (2) Aicardi's Epilepsy in Children, Lippincott Williams &amp; Wilkins, 2004, (3) Progress in Epileptic Spasms and West Syndrome, John Libbey Eurotext, 2007, (4) Epilepsy and Migraine, John Libbey Eurotext, 2009, (5) The Causes of Epilepsy, Cambridge University Press, 2011. (6) Dravet syndrome, John Libbey Eurotext, 2011. (7) Epilepsy and epileptic seizures, Oxford University Press, 2012</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>(1) EU contract number LSH-CT-2006-2011 037315 (EPICURE) FP6 - LIFESCIHEALTH. Subproject Coordinator (2) Tuscany Region. Research Department. Drug treatment and neuroprotection in hypoxic-ischemic brain injury and neonatal? infantile seizures. 2010-2013. Project Coordinator. (3) EC PROGRAM Rare disease: use of clinical trial simulation for the choice and optimization of study Design: Era-Net. 2011 ? 2014. Unit Coordinator. (4) EC. Genetics of cortical gyral dysgenesis and pathophysiology of tubulin-related malformations of cortical development. EU PROGRAM: E-RARE2. 2012-2014. Unit Coordinator. (5) EC FP7, 2013-2018. DESIRE: Development and Epilepsy - Strategies for Innovative Research to improve diagnosis, prevention and treatment in children with difficult to treat Epilepsy. Grant Agreement 6602531; Project Coordinator, 2013-2018. Italian Ministry of Health and Tuscany Region: An integrated approach to unravel the genetic causes and molecular pathogenesis of epileptogenic focal cortical dysplasia. RF-2013-02355240. 2016-2019. Project Coordinator.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>Pisa Foundation. Grant Title: Development of technology for the diagnostic characterisation and post-chemotherapy- radiotherapy monitoring of paediatric brain tumours using ultra high field MRI. 2013-2016. Project Coordinator.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Scheffer</surname>
<given-names>Ingrid E.</given-names>
</name>
<degrees>MBBS, PhD, FRACP</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>(1) Nutricia - Chair Scientific Advisory Board 2017 (2) UCB - Chair Scientific Advisory Board, 2017 (3) BioMarin - Chair Scientific Advisory Board 2017</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for travel or speaker honoraria:</title>
<list-item>
<p>(1) Zogenix: Travel/Conference expenses, speaker 2016 (2) GSK; Travel/Conference expenses. Honoraria, speaker 2016/2017 (3) Eisai; Honoraria, Travel/Conference expenses, speaker 2017 (4) BioMarin; Honoraria, Travel/Conference expenses 2017 (5) National Research Foundation, Singapore: Travel/conference expenses, honoraria 2018</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>(1) Neurology, Editorial Board, 2014-present (2) Epilepsy Currents, Editorial Board, 2014-present (3) Epileptic Disorders, Editorial Board, 2006-present (4) Progress in Epileptic Disorders series, Editorial Board, 2005-present (5) Virtual Neuro Centre, Editorial Board, 2005-present</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>Has received revenue for: (1) Diagnostic and therapeutic methods for EFMR (2) A Diagnostic Method for Epilepsy Issued</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>(1) Ovid Therapeutics: 2018 (2) UCB: 2018</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other activities:</title>
<list-item>
<p>(1) GW Pharmaceuticals: Participated in Epilepsy Drug Consortium as investigator</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>(1) National Health and Medical Research Foundation, Australia: a) CI,Program Grant 2016-2020 b) Practitioner Fellowship 2016-2020 c) Project Grant 2016-2020 (2) CI, Centre for Research Excellence Grant, 2016-2012 (3) CI, Targeted Call for Research into Preparing Australia for the Genomics Revolution in Health Care 2016-2020 (4) National Institute of Health PI, Centres without Walls funding 'Epi4K' 2016-2020 (5) Medical Research Future Fund 2017-2021 (6) Health Research Council New Zealand 2015-2018</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>(1) University of Melbourne School of Health Sciences 2016</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>(1) March Of Dimes Foundation 2015-2016, 2015-2017 (2) Queensland Emergency Medicine Research Foundation 2016-2017 (3) Rebecca L Cooper Medical Research Foundation 2016</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>Diagnostic and Therapeutic Methods for EFMR (Epilepsy and Mental Retardation Limited to Females)</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<aff>From the Epilepsy Research Centre (D.R.M.V., B.J.S., R.B., M.F.B., S.F.B., M.S.H., I.E.S.), Department of Medicine, University of Melbourne, Austin Health, Australia; Departments of Genetics (D.R.M.V., C.M.A.v.R.-A.) and Neurology (D.R.M.V.), University Medical Center Groningen, University of Groningen, the Netherlands; Pediatric Neurology Unit and Laboratories (D.M., M.M.) and Pediatric Neurology (R.G.), Neurogenetics and Neurobiology Unit and Laboratories, A. Meyer Children's Hospital, University of Florence, Italy; Department of Pediatrics and Pediatric Epilepsy Centre (H.X., W.X.W., Y.J.), Peking University First Hospital, Beijing, China; Department of Pediatrics (C.T.M., H.C.M.), Division of Genetic Medicine, University of Washington, Seattle; Population Health and Immunity Division (M.F.B.), Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia; Department of Medical Biology (M.F.B.), University of Melbourne, Australia; Caulfield (D.W.), Melbourne, Australia; Department of Clinical Genetics (S.M.M.), Academic Medical Centre, Amsterdam, the Netherlands; Department of Clinical Genetics (A.S.B., G.M.S.M., I.M.B.H.v.d.L.), Erasmus University Medical Centre, Rotterdam, the Netherlands; Department of Clinical Genetics (J.M.v.H.), VU University Medical Center, Amsterdam, the Netherlands; Tasmanian Health Service (T.L.W.), Women's and Children's Services, Launceston General Hospital, Tasmania, Australia; TY Nelson Department of Neurology and Neurosurgery (R.I.W.) and Institute of Neuroscience and Muscle Research (R.I.W.), Children's Hospital at Westmead, Sydney, Australia; Department of Neurosciences (S.M.), Lady Cilento Children's Hospital, Brisbane, Australia; Department of Anatomical Pathology (R.M.K.), Austin Hospital, Melbourne, Australia; IRCCS Stella Maris Foundation (F.S., R.G.), Pisa, Italy; Klinikum Oldenburg (G.C.K.), Zentrum für Kinder-und Jugendmedizin, Klinik für Neuropädiatrie u. angeborene Stoffwechselerkrankungen, Oldenburg, Germany; Centre of Epilepsy (Y.J.), Beijing Institute for Brain Disorders, China; Department of Paediatrics (I.E.S.), University of Melbourne, Royal Children's Hospital, Australia; and Florey Institute of Neurosciences and Mental Health (I.E.S.), Parkville, Australia.</aff>
</contrib-group>
<author-notes>
<corresp><bold>Correspondence</bold> Dr. Scheffer <email>scheffer@unimelb.edu.au</email></corresp>
<fn fn-type="financial-disclosure">
<p>Go to <ext-link ext-link-type="uri" xlink:href="http://n.neurology.org/lookup/doi/10.1212/WNL.0000000000006729">Neurology.org/N</ext-link> for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.</p>
</fn>
<fn fn-type="other">
<p>The Article Processing Charge was funded by the authors.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<day>08</day>
<month>1</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>08</day>
<month>1</month>
<year>2019</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="ppub"/>. -->
<volume>92</volume>
<issue>2</issue>
<fpage>e96</fpage>
<lpage>e107</lpage>
<history>
<date date-type="received">
<day>05</day>
<month>3</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>27</day>
<month>8</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</copyright-statement>
<copyright-year>2018</copyright-year>
<copyright-holder>American Academy of Neurology</copyright-holder>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND)</ext-link>, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p>
</license>
</permissions>
<self-uri xlink:href="NEUROLOGY2018890111.pdf" xlink:title="pdf"></self-uri>
<abstract>
<sec>
<title>Objective</title>
<p>To delineate the epileptology, a key part of the <italic>SYNGAP1</italic> phenotypic spectrum, in a large patient cohort.</p>
</sec>
<sec>
<title>Methods</title>
<p>Patients were recruited via investigators' practices or social media. We included patients with (likely) pathogenic <italic>SYNGAP1</italic> variants or chromosome 6p21.32 microdeletions incorporating <italic>SYNGAP1</italic>. We analyzed patients' phenotypes using a standardized epilepsy questionnaire, medical records, EEG, MRI, and seizure videos.</p>
</sec>
<sec>
<title>Results</title>
<p>We included 57 patients (53% male, median age 8 years) with <italic>SYNGAP1</italic> mutations (n = 53) or microdeletions (n = 4). Of the 57 patients, 56 had epilepsy: generalized in 55, with focal seizures in 7 and infantile spasms in 1. Median seizure onset age was 2 years. A novel type of drop attack was identified comprising eyelid myoclonia evolving to a myoclonic-atonic (n = 5) or atonic (n = 8) seizure. Seizure types included eyelid myoclonia with absences (65%), myoclonic seizures (34%), atypical (20%) and typical (18%) absences, and atonic seizures (14%), triggered by eating in 25%. Developmental delay preceded seizure onset in 54 of 56 (96%) patients for whom early developmental history was available. Developmental plateauing or regression occurred with seizures in 56 in the context of a developmental and epileptic encephalopathy (DEE). Fifty-five of 57 patients had intellectual disability, which was moderate to severe in 50. Other common features included behavioral problems (73%); high pain threshold (72%); eating problems, including oral aversion (68%); hypotonia (67%); sleeping problems (62%); autism spectrum disorder (54%); and ataxia or gait abnormalities (51%).</p>
</sec>
<sec>
<title>Conclusions</title>
<p><italic>SYNGAP1</italic> mutations cause a generalized DEE with a distinctive syndrome combining epilepsy with eyelid myoclonia with absences and myoclonic-atonic seizures, as well as a predilection to seizures triggered by eating.</p>
</sec>
</abstract>
<funding-group>
<award-group>
<funding-source>Medical Research Council</funding-source>
<award-id>1091593, 2016–2020, 1104831, 2016–2020</award-id>
</award-group>
<award-group>
<funding-source>NIH</funding-source>
<award-id>1R01NS069605</award-id>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>OPEN-ACCESS</meta-name>
<meta-value>TRUE</meta-value>
</custom-meta>
<custom-meta>
<meta-name>STATUS</meta-name>
<meta-value>ONLINE-ONLY</meta-value>
</custom-meta>
<custom-meta>
<meta-name>special-property</meta-name>
<meta-value>video</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<p>Mutations of the <italic>SYNGAP1</italic> gene were first identified in 2009 in patients with nonsyndromic intellectual disability (ID) and autism spectrum disorder (ASD), followed in 2013 by recognition of their important role in the developmental and epileptic encephalopathies (DEEs).<sup><xref ref-type="bibr" rid="R1">1</xref><xref ref-type="bibr" rid="R2">–</xref><xref ref-type="bibr" rid="R3">3</xref></sup> Most affected individuals have de novo mutations, with truncating mutations predominating, although missense mutations, chromosomal translocations, or microdeletions disrupting <italic>SYNGAP1</italic> are also described.<sup><xref ref-type="bibr" rid="R4">4</xref><xref ref-type="bibr" rid="R5">–</xref><xref ref-type="bibr" rid="R8">8</xref></sup></p>
<p><italic>SYNGAP1</italic> (MIM *603384) on chromosome 6p21.32 encodes a synaptic Ras-GTPase-activating protein, expressed mainly in the synapses of excitatory neurons.<sup><xref ref-type="bibr" rid="R9">9</xref>,<xref ref-type="bibr" rid="R10">10</xref></sup> SYNGAP1 is a key mediator in the NMDA receptor activated RAS-signaling cascade regulating the postsynaptic density and the formation, development, and maturation of dendritic spines.<sup><xref ref-type="bibr" rid="R11">11</xref>,<xref ref-type="bibr" rid="R12">12</xref></sup> Loss of function of SYNGAP1 has major consequences for neuronal homeostasis and development, which are crucial for learning and memory.<sup><xref ref-type="bibr" rid="R11">11</xref></sup>
<italic>Syngap1</italic>-null mice die within a week, and <italic>Syngap1</italic>-heterozygous mutant mice have a lower seizure threshold, learning and memory deficits, and behavioral problems.<sup><xref ref-type="bibr" rid="R13">13</xref><xref ref-type="bibr" rid="R14">–</xref><xref ref-type="bibr" rid="R16">16</xref></sup></p>
<p>Since our original description of 5 patients with an <italic>SYNGAP1</italic>-DEE,<sup><xref ref-type="bibr" rid="R3">3</xref></sup> 2 additional studies have described the epilepsy in 24 of 27 patients with <italic>SYNGAP1</italic> encephalopathy; the specific epilepsy syndrome was described in only 4 of these cases.<sup><xref ref-type="bibr" rid="R8">8</xref>,<xref ref-type="bibr" rid="R17">17</xref></sup>
<italic>SYNGAP1</italic> was originally identified in 38 patients with ID or ASD, of whom 15 had seizures and only 1 had an epilepsy syndrome diagnosis.<sup><xref ref-type="bibr" rid="R1">1</xref>,<xref ref-type="bibr" rid="R2">2</xref>,<xref ref-type="bibr" rid="R4">4</xref><xref ref-type="bibr" rid="R5">–</xref><xref ref-type="bibr" rid="R7">7</xref>,<xref ref-type="bibr" rid="R18">18</xref><xref ref-type="bibr" rid="R19">–</xref><xref ref-type="bibr" rid="R28">28</xref></sup> We aimed to delineate the epilepsy syndromes within the <italic>SYNGAP1</italic> phenotypic spectrum in a large international cohort of patients with <italic>SYNGAP1</italic> mutations and microdeletions.</p>
<sec id="s1" sec-type="methods">
<title>Methods</title>
<sec id="s1-1">
<title>Study cohort</title>
<p>We recruited 66 patients with <italic>SYNGAP1</italic> variants via investigators' practices in Australia, Italy, the Netherlands, and China (n = 39) and via the <italic>SYNGAP1</italic> Facebook group on which parents posted our invitation to participate (n = 27). The pathogenicity of all <italic>SYNGAP1</italic> variants was evaluated with the use of standard American College of Medical Genetics and Genomics guidelines (table e-1, available from Dryad, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5061/dryad.ck70sj0">doi.org/10.5061/dryad.ck70sj0</ext-link>).<sup><xref ref-type="bibr" rid="R29">29</xref></sup> We included 57 (86%) patients with (likely) pathogenic <italic>SYNGAP1</italic> variants (n = 53) or chromosome 6p21.32 microdeletions including <italic>SYNGAP1</italic> and other genes (n = 4). Five (8%) patients with a <italic>SYNGAP1</italic> variant of unknown significance were studied separately. Four (6%) patients with likely benign <italic>SYNGAP1</italic> variants were excluded.</p>
</sec>
<sec id="s1-2">
<title>Phenotyping</title>
<p>Parents or caregivers of all patients were interviewed with a standardized epilepsy questionnaire.<sup><xref ref-type="bibr" rid="R30">30</xref></sup> We analyzed medical records, EEGs, neuroimaging, including MRI results, and, when available, seizure videos and video-EEG data. Seizure types and syndromes were classified with the 2017 International League Against Epilepsy classification.<sup><xref ref-type="bibr" rid="R31">31</xref>,<xref ref-type="bibr" rid="R32">32</xref></sup> The severity of ID was established with IQ scores (when available) or information on the level of functioning in accordance with the DSM-V.<sup><xref ref-type="bibr" rid="R33">33</xref></sup></p>
</sec>
<sec id="s1-3">
<title>Genotyping</title>
<p><italic>SYNGAP1</italic> mutations were described on the basis of the longest isoform 1 of <italic>SYNGAP1 (NM_0067772.2)</italic><sup><xref ref-type="bibr" rid="R34">34</xref></sup> and chromosomal microdeletions on the basis of the Genome Reference Consortium Human Reference sequence version 37 (GRCh37/hg19).</p>
</sec>
<sec id="s1-4">
<title>Genotype-phenotype correlation</title>
<p>We examined genotype-phenotype correlations in 4 patient groups: (1) truncating mutations, which included nonsense and frameshift mutations; (2) splice-site mutations; (3) missense and in-frame insertion/deletion mutations; and (4) chromosome 6p21.32 microdeletions including <italic>SYNGAP1</italic> and other genes. Splice-site mutations were considered separately because their effects on the protein are variable.<sup><xref ref-type="bibr" rid="R35">35</xref></sup></p>
</sec>
<sec id="s1-5">
<title>Standard protocol approvals, registrations, and patient consents</title>
<p>All parents or legal representatives of the patients gave written informed consent for inclusion and use of photos and videos. This study was approved by the local institutional Ethics Committee (Austin Health reference No. H2007/02961).</p>
</sec>
<sec id="s1-6" sec-type="data-availability">
<title>Data availability</title>
<p>Anonymized data will be shared by request from any qualified investigator.</p>
</sec>
</sec>
<sec id="s2" sec-type="results">
<title>Results</title>
<sec id="s2-1">
<title>Cohort</title>
<p>Fifty-seven patients (53% male, median age at study 8 years) with (likely) pathogenic <italic>SYNGAP1</italic> variants were included: 34 truncating, 8 splice-site, and 11 missense/in-frame mutations and 4 microdeletions. Forty-six (81%) patients have not been previously reported. Thirty-nine of these patients had novel mutations, which included a total of 35 unique mutations because 4 were recurrent. The remaining 7 individuals had previously reported mutations. <xref ref-type="fig" rid="F1">Figure 1A</xref> depicts the 57 <italic>SYNGAP1</italic> mutations and microdeletions found in our patient cohort, and <xref ref-type="fig" rid="F1">figure 1B</xref> shows the 62 <italic>SYNGAP1</italic> variants of all previously reported patients who were not included in our cohort.<sup><xref ref-type="bibr" rid="R1">1</xref>,<xref ref-type="bibr" rid="R2">2</xref>,<xref ref-type="bibr" rid="R4">4</xref><xref ref-type="bibr" rid="R5">–</xref><xref ref-type="bibr" rid="R8">8</xref>,<xref ref-type="bibr" rid="R17">17</xref><xref ref-type="bibr" rid="R18">–</xref><xref ref-type="bibr" rid="R28">28</xref></sup> Inheritance was tested in 53 of 57 patients, and the mutation had arisen de novo in all<italic>.</italic>
<xref ref-type="table" rid="T1">Table 1</xref> describes the clinical features for our cohort according to the 4 genotypic groups. More detailed individual genetic and phenotypic are summarized in tables e-1 and e-2 (available from Dryad, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5061/dryad.ck70sj0">doi.org/10.5061/dryad.ck70sj0</ext-link>).</p>
<fig id="F1" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<title>Schematic presentation of <italic>SYNGAP1</italic> mutations and microdeletions (A) in patients of our cohort or (B) previously published in the literature</title>
<p>Chromosome 6p21.32 microdeletions including <italic>SYNGAP1</italic>, are presented as gray bars with &lt;&lt; and &gt;&gt; indicating that their breakpoints were outside the region presented here. Truncating (◆) and splice-site (→) mutations are presented above the gene, and missense and in-frame (•) mutations are shown underneath the gene. Bold variants concern recurrent variants that were identified in our cohort but also previously published in the literature. Colors of the lines represent the epilepsy syndrome phenotype: moderate to severe developmental and epileptic encephalopathy (red), moderate to severe developmental encephalopathy with epilepsy (orange), moderate to severe developmental encephalopathy with no epilepsy (blue), mild developmental and epileptic encephalopathy (light green), mild developmental encephalopathy with no epilepsy (dark green), and unknown/unclassified epilepsy (gray). Chromosomal coordinates were based on National Center for Biotechnology Information Build 37 [hg19] and <italic>SYNGAP1</italic> mutations, protein domains, and exons on the longest isoform 1 (NM_006772.2).</p>
</caption>
<graphic xlink:href="NEUROLOGY2018890111FF1"></graphic>
</fig>
<table-wrap id="T1" orientation="portrait" position="float">
<label>Table 1</label>
<caption>
<p>Phenotypes in patients with <italic>SYNGAP1</italic> mutations and microdeletions</p>
</caption>
<graphic xlink:href="NEUROLOGY2018890111TT1"></graphic>
<graphic xlink:href="NEUROLOGY2018890111TT1A"></graphic>
</table-wrap>
</sec>
<sec id="s2-2">
<title>Seizure types</title>
<p>Fifty-six of 57 patients had epilepsy with a median age at seizure onset of 2 years (range 4 months–7 years, known in 55). At onset, 50 patients had generalized seizures, 1 had infantile spasms in the context of West syndrome, 3 had possible focal seizures, and 2 had unknown seizure types.</p>
<p>Absence seizures occurred in 53 of 57 (93%) patients: eyelid myoclonia (EM) with absences in 37, atypical absences in 11, typical absences in 10, and myoclonic absences in 2. Other seizure types included myoclonic (19 of 57, 33%), atonic (8 of 57, 12%), myoclonic-atonic (3 of 57, 5%), and unclassified drop attacks (2 of 57, 4%). Fourteen (25%) patients had tonic-clonic seizures (TCS), of whom 2 also had focal seizures. Five patients had focal seizures without TCS. Four of 57 (7%) patients had febrile seizures before epilepsy onset.</p>
<p>Reflex seizures were seen, often occurring in clusters, and triggered by eating (25%), sound (7%), or touch (4%). Hunger was also associated with seizures in 7%. Clinical photosensitivity occurred in 13 (23%) patients and EEG photosensitivity in 17 of 31 (55%) tested. Three (5%) patients had self-induced seizures with hyperventilation.</p>
</sec>
<sec id="s2-3">
<title>Novel seizure type: EM-myoclonic-atonic seizures</title>
<p>Of the 36 patients with EM, we observed a novel seizure type in 13 of 36 (36%) in whom the EM evolved to a drop attack. The nature of the drop attack was an EM-myoclonic-atonic seizure in 5 and an EM-atonic seizure in 8 patients (<xref ref-type="supplementary-material" rid="SM1">video 1</xref>). Ictal EEG showed generalized spike wave (GSW) discharges coinciding with the EM, followed by a spike-wave complex correlating with the myoclonic (spike) and atonic (slow wave) component (<xref ref-type="fig" rid="F2">figure 2</xref>). We also observed that EM seizures were accompanied by myoclonic jerks of the limbs in 4 of 36 (11%) patients. These novel seizure types, EM-myoclonic-atonic and EM-atonic, occurred mainly when EM clustered and at times of poor seizure control.</p>
<p>
<supplementary-material content-type="local-data" id="SM1">
<object-id pub-id-type="doi">10.1212/006729_Video_1</object-id>
<label>Video 1</label>
<caption>
<p>EM-myoclonic-atonic seizure in five and an EM-atonic seizure in eight patients.<inline-supplementary-material content-type="local-data" id="d35e4890" mime-subtype="mp4" mimetype="video" xlink:href="006729_Video_1.mp4">Download Supplementary Video 1</inline-supplementary-material> via <ext-link ext-link-type="uri" xlink:href="10.1212/006729_Video_1">http://dx.doi.org/10.1212/006729_Video_1</ext-link></p>
</caption>
</supplementary-material>
</p>
<fig id="F2" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<title>Ictal EEG registration during eyelid myoclonia–myoclonic–atonic seizure</title>
<p>Red arrows indicate the different phases of the seizure associated with a generalized spike wave (eyelid myoclonia) and a further spike wave correlating with the myoclonic (spike) and atonic (wave) components.</p>
</caption>
<graphic xlink:href="NEUROLOGY2018890111FF2"></graphic>
</fig>
</sec>
<sec id="s2-4">
<title>Neurodevelopment and behavioral issues</title>
<p>Developmental delay was identified soon after birth in 55 of 56 (96%) patients and preceded seizure onset in all. Development regressed or plateaued with seizure onset in 56 patients. Language was severely impaired, with 12 patients being nonverbal, at age 2 to 33 years. ID was present in 55 of 57 patients, being moderate to severe in 50 and mild in 5.</p>
<p>Behavioral problems were seen in 41 of 56 (73%) patients and were often severe with oppositional and defiant behavior with aggression, self-injury, and tantrums. ASD was diagnosed in 30 (53%) patients.</p>
</sec>
<sec id="s2-5">
<title>Other features</title>
<p>An interesting observation was that the families of 39 of 54 (72%) patients noted that they had a high pain threshold. Patients did not respond to painful events such as a fractured bone, surgical incision of a lesion, or a foreign object lodged in their foot.</p>
<p>Difficulties with eating were a major problem in 39 (68%) patients. Twenty-three patients had a poor intake because they were fussy about food type, color, texture, and temperature (16) or had oral aversion (5), oral hypersensitivity (3), and poor appetite (3). Four patients needed a nasogastric tube because of the severity of their eating problems. In contrast, 7 patients had uncontrolled eating with gorging, and 3 would eat inedible objects. Eleven of 55 patients had difficulties with transition from fluids to solid food in early childhood. Seventeen of 56 patients had chewing and swallowing difficulties.</p>
<p>Sleep was disturbed in 34 of 55 (62%) patients with difficulties initiating (n = 19) and maintaining (n = 29) sleep. Improved seizure control led to better sleep in 12 patients. There was no clear correlation with EEG features; there was an increase in epileptiform activity in sleep in 9 of 23 (39%) patients with sleep difficulties, which was also observed in 6 of 12 (50%) without sleep difficulties. Sleep also improved with melatonin (n = 10), clonidine (n = 5), and trazodone (n = 1).</p>
</sec>
<sec id="s2-6">
<title>Examination findings</title>
<p>Photographs of 31 of 57 patients were available (<xref ref-type="fig" rid="F3">figure 3</xref>) and revealed subtle dysmorphic features, not present in all patients. These included full, slightly prominent eyebrows with medial flaring in some; hypertelorism; full nasal tip, slightly upturned nasal tip in younger children; short philtrum; cupid bow upper lip; broad mouth with diastemata of the upper teeth; and small pointed chin.</p>
<fig id="F3" orientation="portrait" position="float">
<label>Figure 3</label>
<caption>
<title><italic>SYNGAP1</italic> dysmorphology</title>
<p>Portrait photographs from 31 of 56 patients with <italic>SYNGAP1</italic> mutations or microdeletions including <italic>SYNGAP1</italic>. (A) Patient 4, (B) patient 6, (C) patient 7, (D), patient 8 (sibling of patient 9), (E) patient 9 (sibling of patient 8), (F) patient 12, (G) patient 13, (H) patient 14, (I) patient 16, (J) patient 18, (K) patient 19, (L) patient 20, (M) patient 21, (N) patient 23, (O) patient 25, (P) patient 27, (Q) patient 28, (R) patient 29, (S) patient 31, (T) patient 32, (U) patient 33, (V) patient 34, (W) patient 35, (X) patient 37, (Y) patient 45, (Z) patient 47, (AA) patient 50, (AB) patient 51, (AC) patient 52, (AD) patient 54 (monozygotic twin with patient 55), and (AE) patient 55 (monozygotic twin with patient 54).</p>
</caption>
<graphic xlink:href="NEUROLOGY2018890111FF3"></graphic>
</fig>
<p>Neurologic examination showed hypotonia in 38 (67%), ataxia or an unsteady gait in 29 (51%), tremor in 5 (9%), and microcephaly in 1 (2%) of 54. Orthopedic abnormalities included foot or spine deformities in 16 (28%), including pes planus (7), pronated feet (4), scoliosis (3), pes cavus (1), congenital hip dislocation (1), or congenital hip dysplasia (1).</p>
</sec>
<sec id="s2-7">
<title>EEG findings</title>
<p>EEG results were available for 52 of 57 patients from when their epilepsy was active. Many children did not have further EEGs because of severe behavioral problems. GSW and generalized poly-spike wave were reported in 39 of 52 (75%) patients. Focal or multifocal epileptiform discharges were seen in 28 of 52 (54%), often in addition to GSW or generalized poly-spike wave (21 of 39, 54%). Slow background activity was seen in 26 of 52 (50%) patients.</p>
</sec>
<sec id="s2-8">
<title>Neuroimaging</title>
<p>MRI was reported as normal in 37 of 53 (70%) patients. One patient had a left frontal subcortical nodular heterotopia. The 15 remaining patients had nonspecific findings: thin corpus callosum (3; 2 of 3 also had a thin chiasma opticum), enlarged ventricles or subarachnoid spaces (3), hyperintense T2 signals in the white matter (3), posterior centrum semiovale (2) or fasciculus longitudinalis medialis (1), patent cavum vergae (1), atypical white matter abnormalities (1), mega cisterna magna fossa posterior (1), discrete hippocampal tissue loss (1), or a pineal cyst (1).</p>
</sec>
<sec id="s2-9">
<title>Brain pathology</title>
<p>Brain pathology was available from patient 14, a 33-year-old nonverbal woman with a de novo <italic>SYNGAP1</italic> nonsense mutation (<xref ref-type="supplementary-material" rid="SM2">video 2</xref>), who died of aspiration pneumonia. The pathology showed cerebellar Purkinje cell loss with associated astrocytosis (<xref ref-type="fig" rid="F4">figure 4A</xref>). Astrocytosis was found predominantly in the superficial cortical layer but also in the hippocampi and deep gray nuclei (<xref ref-type="fig" rid="F4">figure 4B</xref>). Macroscopic evaluation showed a low brain weight (1,194 g, −3.2 SD) with widely but moderately distributed leptomeningeal fibrosis, most evident over the frontal lobes (<xref ref-type="fig" rid="F4">figure 4C</xref>). Cortical neurons did not show evidence of anoxic ischemic injury (data not shown).</p>
<p>
<supplementary-material content-type="local-data" id="SM2">
<object-id pub-id-type="doi">10.1212/006729_Video_2</object-id>
<label>Video 2</label>
<caption>
<p>Brain pathology was available from patient 14, a 33 year old non-verbal woman with a de novo SYNGAP1 nonsense mutation.<inline-supplementary-material content-type="local-data" id="d35e4986" mime-subtype="mp4" mimetype="video" xlink:href="006729_Video_2.mp4">Download Supplementary Video 2</inline-supplementary-material> via <ext-link ext-link-type="uri" xlink:href="10.1212/006729_Video_2">http://dx.doi.org/10.1212/006729_Video_2</ext-link></p>
</caption>
</supplementary-material>
</p>
<fig id="F4" orientation="portrait" position="float">
<label>Figure 4</label>
<caption>
<title>Brain pathology in a patient with an <italic>SYNGAP1</italic> mutation</title>
<p>(A) Glial fibrillary acidic protein (GFAP)–stained section of the cerebellar cortex showing a single surviving Purkinje cell (arrow points toward this cell) in a field of Purkinje cell loss and mild internal granular layer and cerebellar molecular layer astrocytosis. (B) GFAP staining of dentate gyrus showing no neuronal loss but mild reactive astrocytosis in the dentate granular layer and the dentate molecular layer of the hippocampus. (C) Vertex view of the cerebral hemispheres showing leptomeningeal fibrosis.</p>
</caption>
<graphic xlink:href="NEUROLOGY2018890111FF4"></graphic>
</fig>
</sec>
<sec id="s2-10">
<title>Epilepsy syndrome</title>
<p>A distinctive generalized epilepsy phenotype emerged combining features of 2 well-described syndromes, epilepsy with eyelid myoclonia with absences, reported by Jeavons,<sup><xref ref-type="bibr" rid="R36">36</xref></sup> and epilepsy with myoclonic-atonic seizures, described by Doose et al.<sup><xref ref-type="bibr" rid="R37">37</xref></sup> The overall gestalt in 56 of 57 patients was a spectrum of severity of generalized DEE with multiple seizure types, including EM, myoclonic, and atonic (and combinations of all 3). TCS were fairly frequent, whereas focal seizures occurred in a minority. The majority of patients had a severe outcome with moderate to severe ID (49 of 56, 88%), while 7 of 56 (12%) had a milder outcome with normal intellect or mild ID. One child with a mild outcome had West syndrome. The remaining patient with no seizures but epileptiform abnormalities on EEG had a (static) developmental encephalopathy with a severe outcome. Another distinctive feature of <italic>SYNGAP1</italic>, seen in a quarter of cases, was the presence of reflex seizures triggered by eating.</p>
</sec>
<sec id="s2-11">
<title>Epilepsy treatment and outcome</title>
<p>Overall, 20 different antiepileptic drugs (AEDs) were started (table e-3, available from Dryad, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5061/dryad.ck70sj0">doi.org/10.5061/dryad.ck70sj0</ext-link>). Valproate and lamotrigine were most commonly prescribed (n = 45 and n = 22), with ongoing prescription of lamotrigine for 77% of patients and valproate for 64% patients. Of the 6 patients who had received cannabidiol, 5 of 6 (83.3%) remained on it.</p>
<p>Thirty-five of 56 (63%) patients had refractory epilepsy with ongoing seizures after 2 AEDs. Six became seizure-free on the third to sixth AED. In total, 10 of 56 (18%) patients became seizure-free at 7 years of age (median, range 3–13 years). Of these, seizures were controlled on monotherapy with valproate (3), levetiracetam (1), or steroids (1, for infantile spasms). Polytherapy combinations resulting in seizure freedom included levetiracetam and topiramate (1), valproate and lamotrigine (1), and cannabidiol, valproate, and lamotrigine (1). Two were seizure-free on no treatment. Four patients had no seizures for a period of 6 months to 7 years while treated with carbamazepine (1), lamotrigine (1), valproate (1), or valproate, lamotrigine, and clobazam, but seizures recurred.</p>
</sec>
<sec id="s2-12">
<title>Genotype-phenotype correlation</title>
<p>The phenotypes of patients with truncating, splice-site, or missense/in-frame mutations and microdeletions were similar overall, except that 4 patients with microdeletions all had an earlier seizure onset (20 months compared with 2 years in the remaining cohort, <xref ref-type="table" rid="T1">table 1</xref>). All 4 patients had microdeletions that included additional genes (4–13 genes). In terms of the outcome, all 4 cases had severe ID, consistent with the rest of the cohort. Given their similar epileptology and other features (high pain threshold in 2, poor oral intake in 2, seizures triggered by hunger and photosensitivity in 1, and dysmorphic features in 2), we included them in the total cohort.</p>
<p>For evaluating genotype-phenotype correlations, we separated <italic>SYNGAP1</italic> encephalopathies into 2 groups based on severity determined by their intellect. Milder phenotypes included normal intellect or mild ID; severe phenotypes referred to moderate to severe ID. Of the 7 patients with a milder phenotype (green mutations, <xref ref-type="fig" rid="F1">figure 1A</xref>), 5 had a truncating or splice-site mutation, of which 4 were located in exons 1 to 4. Two other patients had a missense variant in exons 6 and 11. Five previously reported patients also had a milder phenotype (green and dark green mutations, <xref ref-type="fig" rid="F1">figure 1B</xref>), with 3 of 5 having mutations in exons 1 to 4. In the combined cohort of our and previously reported patients, milder phenotypes were significantly more often observed in patients with mutation or deletions in exons 1 to 4 (50%, n = 6 of 12) compared to exons 5 to 19 (7%, 6 of 85, <italic>p</italic> = 0.001, Fisher exact test). No significant differences were observed in outcome between patients with different mutation types (data not shown).</p>
</sec>
<sec id="s2-13">
<title>Patients with <italic>SYNGAP1</italic> variants of unknown significance (n = 5)</title>
<p>Not included in our cohort of 56 patients were 5 individuals with an <italic>SYNGAP1</italic> variant of unknown significance. Tables e-1 and e-2 (available from Dryad, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5061/dryad.ck70sj0">doi.org/10.5061/dryad.ck70sj0</ext-link>) show details of their pathogenicity predictions and associated phenotypes. Three patients who had variants reported in gnomAD or ExAC and for whom inheritance of their <italic>SYNGAP1</italic> variant was unavailable had phenotypes that were consistent with our large cohort.<sup><xref ref-type="bibr" rid="R38">38</xref></sup> Two had generalized DEE and 1 had mild ID with EM. Their presence in population databases is difficult to explain, although EM can be subtle and easily missed. It remains to be determined whether their <italic>SYNGAP1</italic> variant has a role in their presentation. The remaining 2 had variants with lower conservation and pathogenicity prediction scores and had focal epilepsy with or without ID, so their phenotype was quite different.</p>
</sec>
</sec>
<sec id="s3" sec-type="discussion">
<title>Discussion</title>
<p><italic>SYNGAP1</italic> is an important gene for the DEEs, present in 1% of our original cohort of patients with unsolved DEEs,<sup><xref ref-type="bibr" rid="R3">3</xref>,<xref ref-type="bibr" rid="R8">8</xref>,<xref ref-type="bibr" rid="R17">17</xref></sup> having been first identified as a gene for ID.<sup><xref ref-type="bibr" rid="R1">1</xref></sup> Here, we describe a distinctive generalized DEE phenotype for <italic>SYNGAP1</italic> combining syndromic features of epilepsy with eyelid myoclonia with absences (EMA) and epilepsy with myoclonic-atonic seizures (MAE) (<xref ref-type="fig" rid="F5">figure 5</xref>). <italic>SYNGAP1</italic> encephalopathy was associated with a spectrum of mild (8%) to severe (88%) ID and a range of other comorbid conditions (<xref ref-type="fig" rid="F6">figure 6</xref>). Seizures were often triggered by eating. The 1 patient without a DEE had a static developmental encephalopathy without seizures but had epileptiform abnormalities on EEG.</p>
<fig id="F5" orientation="portrait" position="float">
<label>Figure 5</label>
<caption>
<title><italic>SYNGAP1</italic> encephalopathy</title>
<p>This conceptual diagram highlights that the most common epilepsy phenotype in our cohort was an overlapping syndrome combining the features of 2 well-recognized epilepsy syndromes: epilepsy with eyelid myoclonia with absences (EMA) and epilepsy with myoclonic-atonic seizures (MAE). About one-third of the cohort did not fit into either of these syndromes and had nonsyndromic developmental and epileptic encephalopathy (DEE). One case had West syndrome. Other individuals with <italic>SYNGAP1</italic> encephalopathy may have developmental encephalopathy (intellectual disability) without epilepsy.</p>
</caption>
<graphic xlink:href="NEUROLOGY2018890111FF5"></graphic>
</fig>
<fig id="F6" orientation="portrait" position="float">
<label>Figure 6</label>
<caption>
<title>Comorbidities of <italic>SYNGAP1</italic> encephalopathy</title>
<p>The figure shows the percentage of each comorbidity associated with <italic>SYNGAP1</italic> encephalopathy in our cohort. Dark red denotes moderate to severe intellectual disability; light red denotes mild intellectual disability.</p>
</caption>
<graphic xlink:href="NEUROLOGY2018890111FF6"></graphic>
</fig>
<p><italic>SYNGAP1-</italic>DEE shares many of the striking features of the syndrome of EMA.<sup><xref ref-type="bibr" rid="R39">39</xref></sup> The key seizure type, absences with EM, together with photosensitivity, was found in the majority (64% and 55%, respectively) of our cohort. The onset of EM was earlier for <italic>SYNGAP1</italic>-DEE (&lt;3 years) compared with the classic syndrome of EMA (peak onset 6–8 years).<sup><xref ref-type="bibr" rid="R39">39</xref></sup> In addition, EMA is often associated with better cognitive outcome, with individuals being of normal intellect or having mild ID. An earlier age at onset (&lt;3 years) of EM is associated with poorer intellectual outcome, and perhaps some of these individuals have <italic>SYNGAP1</italic> mutations.<sup><xref ref-type="bibr" rid="R40">40</xref><xref ref-type="bibr" rid="R41">–</xref><xref ref-type="bibr" rid="R43">43</xref></sup> However, there is debate as to whether the diagnosis of EMA allows for the presence of additional seizures types.<sup><xref ref-type="bibr" rid="R40">40</xref></sup> Our <italic>SYNGAP1-</italic>DEE cohort with EM also had myoclonic (33%) and atonic (8%) seizures. We speculate that the more severe cases of EMA may be explained by <italic>SYNGAP1</italic> mutations, especially those individuals with earlier onset of EM or myoclonic or atonic seizures.</p>
<p><italic>SYNGAP1-</italic>DEE also resembles the syndrome of MAE (formerly called myoclonic-astatic epilepsy), as reported in 3 of 11 patients in a previous series.<sup><xref ref-type="bibr" rid="R8">8</xref></sup> Drop attacks are the hallmark of MAE, due to atonic seizures, myoclonic seizures, and MAE. Eleven of 57 patients had features consistent with myoclonic-atonic seizures but with a more severe overall outcome compared with the variable outcome described in MAE.<sup><xref ref-type="bibr" rid="R37">37</xref>,<xref ref-type="bibr" rid="R44">44</xref>,<xref ref-type="bibr" rid="R45">45</xref></sup> Furthermore, severe developmental delay before the onset of seizures in all but 2 patients, together with focal and multifocal epileptiform activity in 57% of cases, mitigates against the classic features of MAE<italic>.</italic><sup><xref ref-type="bibr" rid="R37">37</xref>,<xref ref-type="bibr" rid="R44">44</xref>,<xref ref-type="bibr" rid="R45">45</xref></sup></p>
<p><italic>SYNGAP1</italic> encephalopathy often combines the features of these 2 epilepsy syndromes, EMA and MAE. An overlapping diagnosis of MAE and EMA was present in 35% of our cohort (<xref ref-type="fig" rid="F5">figure 5</xref>). Bringing the 2 syndromic concepts together, we also identified a novel, distinctive seizure type, a drop attack beginning with EM followed by a myoclonic-atonic component (EM-myoclonic-atonic) or simply an atonic component (EM-atonic). We considered EM-myoclonic-atonic and EM-atonic as overlapping seizure types because the myoclonic component could be easily missed (<xref ref-type="supplementary-material" rid="SM1">video 1</xref>). We distinguished EM-(myoclonic)-atonic seizures from atypical absences, which may also include myoclonic and atonic components. First, the myoclonic jerks and atonic seizures were more abrupt and pronounced than in atypical absence seizures, in which subtle jerks and loss of tone can occur. Second, the frequency of GSW was faster (&gt;3 Hz) compared with atypical absences (&lt;2.5 Hz). One reported patient had seizures with blinking followed by a head drop and fall with irregular GSW,<sup><xref ref-type="bibr" rid="R27">27</xref></sup> suggestive of our <italic>SYNGAP1</italic> seizure type.</p>
<p>One patient in our cohort had West syndrome, which has not been associated with <italic>SYNGAP1</italic> before (<xref ref-type="fig" rid="F5">figure 5</xref>). Although atypical absences, present in 20% of our cohort, may suggest a diagnosis of Lennox-Gastaut syndrome, other diagnostic criteria such as tonic seizures and generalized paroxysmal fast activity on EEG were absent. Only 1 patient had nocturnal tonic seizures (patient 19).<sup><xref ref-type="bibr" rid="R46">46</xref></sup></p>
<p>We observed a DEE in all but 1 of our 57 patients, while only 55% of the previously published patients had a DEE (<xref ref-type="fig" rid="F1 F2 F3 F4 F5">figures 1–5</xref>).<sup><xref ref-type="bibr" rid="R6">6</xref>,<xref ref-type="bibr" rid="R17">17</xref>,<xref ref-type="bibr" rid="R22">22</xref></sup> The remaining patients in the literature had a mild to severe developmental encephalopathy with (20%) or without (25%) seizures; it was not possible to determine whether some of these patients may have had a DEE. Our findings that such a high proportion of patients with <italic>SYNGAP1</italic> encephalopathy had a DEE may be due to ascertainment bias because perhaps parents from the <italic>SYNGAP1</italic> Facebook group participated in the study only if they were concerned that their child had seizures. Equally, EM seizures can be very subtle and misinterpreted as a behavioral mannerism. For example, patient 24 was a 9-year-old boy in whom the parents recognized that his eyelid fluttering was seizure activity only after an <italic>SYNGAP1</italic> mutation was identified. Patient 16 had frequent eyelid fluttering from the age of 1 year, but her first EEG was not performed until the age of 10 years and showed frequent epileptiform abnormalities. Her seizures and behavioral and sleep problems all improved after she started AEDs. In 8 patients, developmental regression occurred 2 months to &gt;3 years before the recognition of seizures. Diagnosis of seizures in <italic>SYNGAP1</italic> encephalopathy is thus crucial because appropriate management may potentially improve outcome.</p>
<p>We found that a quarter of patients in our cohort had the distinctive feature that their reflex seizures were triggered by eating, observed previously in a single patient with seizures triggered by chewing.<sup><xref ref-type="bibr" rid="R8">8</xref></sup> The underlying pathophysiologic mechanism for this is unknown. Eating problems, with poor intake or gorging, were also found in more than half of our cohort.</p>
<p>From our historical data, we could not reliably evaluate the efficacy of the prescribed AEDs. Further studies are warranted to explore the efficacy of the drugs, particularly those that appear of benefit such as lamotrigine, valproate, and cannabidiol for <italic>SYNGAP1-</italic>DEE<italic>.</italic></p>
<p><italic>SYNGAP1-</italic>DEE is associated with 4 main comorbid conditions: ID, behavioral problems, a high pain threshold, and ataxia (<xref ref-type="fig" rid="F6">figure 6</xref>). ID was moderate to severe in 88% of patients, with only 2 exhibiting borderline intellect. We might have underestimated the prevalence of milder phenotypes due to ascertainment bias, given our recruitment via Facebook. Severe behavioral problems with oppositional behavior, tantrums, aggression, and self-injury were present in almost three-quarters of patients, as previously observed. One of our most fascinating findings was that three-quarters of the families reported a high pain threshold in their child, often leading to a delay in diagnosis of injuries and inflammation. Parker et al.<sup><xref ref-type="bibr" rid="R17">17</xref></sup> also reported a high pain threshold as an anecdotal observation by some families. This finding of a high pain threshold may suggest a role for <italic>SYNGAP1</italic> in sensory processing.</p>
<p>The neuropathologic study of the brain of a woman with a truncating <italic>SYNGAP1</italic> mutation identified a clear loss of cerebellar Purkinje cells and associated astrocytosis (<xref ref-type="fig" rid="F4">figure 4A</xref>). An unsteady or ataxic gait was identified in 51% of our patients, including this patient. Ataxia or gait abnormalities were also observed in 7 of 10 and 10 of 17 patients reported by Parker et al.<sup><xref ref-type="bibr" rid="R8">17</xref></sup> and Mignot et al.,<sup><xref ref-type="bibr" rid="R8">8</xref></sup> respectively, highlighting that cerebellar features are a key part of the <italic>SYNGAP1</italic>-DEE phenotype.<sup><xref ref-type="bibr" rid="R8">8</xref>,<xref ref-type="bibr" rid="R17">17</xref></sup></p>
<p>Truncating and splice-site mutations occur throughout <italic>SYNGAP1</italic>, while missense mutations mainly cluster in the protein domains.<sup><xref ref-type="bibr" rid="R8">8</xref></sup> A milder outcome of <italic>SYNGAP1</italic>-DEE was observed significantly more frequently in patients with mutations in exons 1 to 4 compared with those with mutations in exons 5 to 19.<sup><xref ref-type="bibr" rid="R8">8</xref></sup> In line with this, Mignot et al.<sup><xref ref-type="bibr" rid="R8">8</xref></sup> also showed that patients with mutations in exons 4 and 5 were more pharmacosensitive compared to those with mutations in exons 6 to 19.<sup><xref ref-type="bibr" rid="R8">8</xref></sup> SYNGAP1 has several isoforms in humans with different promoter sites and alternative splicing; these may explain the variation in phenotypic severity because variants early within the gene transcript often lead to complete loss of the gene product due to nonsense-mediated decay. Further studies on the presence and function of different human isoforms of <italic>SYNGAP1</italic> are warranted to explain the correlation between mutation location and phenotype. Other environmental and genetic factors may also contribute to phenotypic variability. We identified concordant phenotypes in monozygotic twins (patients 53 and 54), similar phenotypes in 2 siblings (patients 8 and 9), yet variable phenotypes in individuals sharing the same mutation (patients 3 and 4, 6 and 7, 24 and 25, 28 and 29, 37 and 38).</p>
<p>We describe <italic>SYNGAP1</italic>-DEE as a predominantly generalized DEE with ID, behavioral problems, a high pain threshold, and ataxia. <italic>SYNGAP1-</italic>DEE combines features of both EMA and MAE. In <italic>SYNGAP1</italic>-DEE, we observed a novel type of drop attack with EM evolving into a myoclonic-atonic or an atonic seizure. Furthermore, a quarter of patients had seizures triggered by eating. Recognition of seizures in the context of <italic>SYNGAP1-</italic>DEE can be challenging but is crucial to optimizing antiepileptic therapy and improving long-term outcome.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="other">
<p>Editorial Page <related-article ext-link-type="doi" id="d35e5362" issue="2" page="63" related-article-type="commentary" vol="92" xlink:href="10.1212/WNL.0000000000006720">63</related-article></p>
</fn>
</fn-group>
<ack>
<title>Acknowledgment</title>
<p>The authors thank all patients and their families for their participation. They are grateful for the support of the <italic>SYNGAP1</italic> parent support group. They thank the Victorian Institute of Forensic Medicine, Dr. Angelika Riess, Dr. Marjolaine Willems, Dr. Einar Bryne, and Dr. Ferdinant Kok for providing clinical information and Dr. Zhixian Yang and Dr. Xiaoyan Liu for EEG review.</p>
</ack>
<sec sec-type="contributions">
<title>Author contributions</title>
<p content-type="contributions">D.R.M. Vlaskamp: drafting and revising manuscript, data analysis, acquisition of data. B.J. Shaw: acquisition of data. R. Burgess: data analysis. D. Mei, M. Montomoli, H. Xie, and W. XiangWei: acquisition of data and data analysis. C.T. Meyers and M.F. Bennett: analysis of <italic>SYNGAP1</italic> variants. D. Williams: initiative of study, study design. S.M. Maas, A.S. Brooks, G.M.S. Mancini, I.M.B.H. van de Laar, J.M. van Hagen, T. Ware, R. Webster, S. Malone, S.F. Berkovic: acquisition of data. R.M. Kalnins: analysis of brain pathology. F. Sicca: acquisition of data. G.C. Korenke: data analysis. C.M.A. van Ravenswaaij-Arts: analysis of dysmorphology, acquisition of data. M.S. Hildebrand, H.C. Mefford: supervision of analysis of <italic>SYNGAP1</italic> variants. Y Jiang: study supervision, revise manuscript, data acquisition. R. Guerrini: study supervision, revise manuscript, acquisition of data. I.E. Scheffer: co-writing manuscript, data analysis, study design.</p>
</sec>
<sec sec-type="funding">
<title>Study funding</title>
<p content-type="funding">Danique R.M. Vlaskamp has received an unrestricted travel grant from the Dutch Society of Child Neurology, Jo Kolk Foundation, and the Research School of Behavioural and Cognitive Neurosciences. Han Xie is supported by the National Natural Science Foundation of China (Youth Foundation) (grant 81501123). Mark F. Bennett is supported by the Victorian State Government Operational Infrastructure Support and Australian Government National Health and Medical Research Council Independent Research Institute Infrastructure Support Scheme. Yuwu Jiang is supported by the Chinese National Key Research Project (2016YFC1306200, 2016–2020). This work was supported in part by a grant from the EU Seventh Framework Programme FP7 under the project DESIRE (grant agreement 602531) to Renzo Guerrini. Ingrid E. Scheffer is supported by a National Health and Medical Research Council Program Grant (1091593, 2016–2020) and Senior Practitioner Fellowship (1104831, 2016–2020).</p>
</sec>
<sec sec-type="disclosure">
<title>Disclosure</title>
<p content-type="disclosure">D. Vlaskamp, B. Shaw, and R. Burgess report no disclosures relevant to the manuscript. D. Mei has received scientific advisory board honoraria from BioMarin Pharmaceutical. M. Montomoli, H. Xie, C. Myers, M. Bennett, W. XiangWei, D. Williams, S. Maas, A. Brooks, G. Mancini, I. van de Laar, J. van Hagen, T. Ware, and R. Webster report no disclosures relevant to the manuscript. S. Malone has received scientific advisory board honoraria from UCB and BioMarin. S. Berkovic, R. Kalnins, F. Sicca, G. Korenke, C. van Ravenswaaij-Arts, and M. Hildebrand report no disclosures relevant to the manuscript. H. Mefford is funded by NIH grant National Institute of Neurological Disorders and Stroke 1R01NS069605. Y. Jiang reports no disclosures relevant to the manuscript. R. Guerrini serves on the editorial boards of <italic>Neurology®</italic> and <italic>Seizure;</italic> has received speaker and consultancy fees from Eisai Inc, Novartis, Zogenix, BioMarin, UCB Pharma, and GW Pharma; receives/has received research support from the European Community, the Italian Ministry of Health, the Mariani Foundation, the Italian Epilepsy Federation, Telethon, the Tuscany Region, the Pisa Foundation, and the Italian Ministry of University and Research. I. Scheffer serves on the editorial boards of <italic>Neurology®e</italic>and <italic>Epileptic Disorders</italic>; may accrue future revenue on a pending patent regarding a therapeutic compound; has received speaker honoraria from Athena Diagnostics, UCB, GSK, Eisai, and Transgenomics; has received scientific advisory board honoraria from Nutricia, UCB and GSK; has received funding for travel from Athena Diagnostics, UCB, and GSK; and receives/has received research support from the National Health and Medical Research Council, Australian Research Council, NIH, Health Research Council of New Zealand, March of Dimes, the Weizmann Institute, Citizens United for Research in Epilepsy, US Department of Defense, and the Perpetual Charitable Trustees. Go to <ext-link ext-link-type="uri" xlink:href="http://n.neurology.org/lookup/doi/10.1212/WNL.0000000000006729">Neurology.org/N</ext-link> for full disclosures.</p>
</sec>
<glossary>
<title>Glossary</title>
<def-list>
<def-item>
<term id="G1">AED</term>
<def>
<p>antiepileptic drug</p>
</def>
</def-item>
<def-item>
<term id="G2">ASD</term>
<def>
<p>autism spectrum disorder</p>
</def>
</def-item>
<def-item>
<term id="G3">DEE</term>
<def>
<p>developmental and epileptic encephalopathy</p>
</def>
</def-item>
<def-item>
<term id="G4">DSM-V</term>
<def>
<p>
<italic>Diagnostic and Statistical Manual of Mental Disorders, 5th edition</italic>
</p>
</def>
</def-item>
<def-item>
<term id="G5">EM</term>
<def>
<p>eyelid myoclonia</p>
</def>
</def-item>
<def-item>
<term id="G6">EMA</term>
<def>
<p>epilepsy with eyelid myoclonia with absences</p>
</def>
</def-item>
<def-item>
<term id="G7">GSW</term>
<def>
<p>generalized spike wave</p>
</def>
</def-item>
<def-item>
<term id="G8">ID</term>
<def>
<p>intellectual disability</p>
</def>
</def-item>
<def-item>
<term id="G9">MAE</term>
<def>
<p>epilepsy with myoclonic-atonic seizures</p>
</def>
</def-item>
<def-item>
<term id="G10">TCS</term>
<def>
<p>tonic-clonic seizures</p>
</def>
</def-item>
</def-list>
</glossary>
<ref-list>
<title>References</title>
<ref id="R1">
<label>1.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamdan</surname><given-names>FF</given-names></name>, <name name-style="western"><surname>Gauthier</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Spiegelman</surname><given-names>D</given-names></name>, <etal>et al</etal></person-group>
<article-title>Mutations in SYNGAP1 in autosomal nonsyndromic mental retardation</article-title>. <source/>N Engl J Med
<year>2009</year>;<volume>360</volume>:<fpage>599</fpage>–<lpage>605</lpage>.<pub-id pub-id-type="pmid">19196676</pub-id></mixed-citation>
</ref>
<ref id="R2">
<label>2.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pinto</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Pagnamenta</surname><given-names>AT</given-names></name>, <name name-style="western"><surname>Klei</surname><given-names>L</given-names></name>, <etal>et al</etal></person-group>
<article-title>Functional impact of global rare copy number variation in autism spectrum disorder</article-title>. <source/>Nature
<year>2010</year>;<volume>466</volume>:<fpage>368</fpage>–<lpage>372</lpage>.<pub-id pub-id-type="pmid">20531469</pub-id></mixed-citation>
</ref>
<ref id="R3">
<label>3.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carvill</surname><given-names>GL</given-names></name>, <name name-style="western"><surname>Heavin</surname><given-names>SB</given-names></name>, <name name-style="western"><surname>Yendle</surname><given-names>SC</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1</article-title>. <source/>Nat Genet
<year>2013</year>;<volume>45</volume>:<fpage>1</fpage>–<lpage>16</lpage>.<pub-id pub-id-type="pmid">23268125</pub-id></mixed-citation>
</ref>
<ref id="R4">
<label>4.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klitten</surname><given-names>LL</given-names></name>, <name name-style="western"><surname>Møller</surname><given-names>RS</given-names></name>, <name name-style="western"><surname>Nikanorova</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Silahtaroglu</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Hjalgrim</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Tommerup</surname><given-names>N</given-names></name></person-group>
<article-title>A balanced translocation disrupts SYNGAP1 in a patient with intellectual disability, speech impairment, and epilepsy with myoclonic absences (EMA)</article-title>. <source/>Epilepsia
<year>2011</year>;<volume>52</volume>:<fpage>190</fpage>–<lpage>193</lpage>.<pub-id pub-id-type="pmid">21219308</pub-id></mixed-citation>
</ref>
<ref id="R5">
<label>5.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krepischi</surname><given-names>ACV</given-names></name>, <name name-style="western"><surname>Rosenberg</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Costa</surname><given-names>SS</given-names></name>, <name name-style="western"><surname>Crolla</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Vianna-Morgante</surname><given-names>AM</given-names></name></person-group>
<article-title>A novel de novo microdeletion spanning the SYNGAP1 gene on the short arm of chromosome 6 associated with mental retardation</article-title>. <source/>Am J Med Genet A
<year>2010</year>;<volume>152A</volume>:<fpage>2365</fpage>–<lpage>2378</lpage>.<pub-id pub-id-type="pmid">20803649</pub-id></mixed-citation>
</ref>
<ref id="R6">
<label>6.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zollino</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Gurrieri</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Orteschi</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Marangi</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Leuzzi</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Neri</surname><given-names>G</given-names></name></person-group>
<article-title>Integrated analysis of clinical signs and literature data for the diagnosis and therapy of a previously undescribed 6p21.3 deletion syndrome</article-title>. <source/>Eur J Hum Genet
<year>2011</year>;<volume>19</volume>:<fpage>239</fpage>–<lpage>242</lpage>.<pub-id pub-id-type="pmid">21119708</pub-id></mixed-citation>
</ref>
<ref id="R7">
<label>7.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Writzl</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Knegt</surname><given-names>AC</given-names></name></person-group>
<article-title>6p21.3 Microdeletion involving the SYNGAP1 gene in a patient with intellectual disability, seizures, and severe speech impairment</article-title>. <source/>Am J Med Genet A
<year>2013</year>;<volume>161A</volume>:<fpage>1682</fpage>–<lpage>1685</lpage>.<pub-id pub-id-type="pmid">23687080</pub-id></mixed-citation>
</ref>
<ref id="R8">
<label>8.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mignot</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Stülpnagel</surname><given-names>CV</given-names></name>, <name name-style="western"><surname>Nava</surname><given-names>C</given-names></name>, <etal>et al</etal></person-group>
<article-title>Genetic and neurodevelopmental spectrum of SYNGAP1-associated intellectual disability and epilepsy</article-title>. <source/>J Med Genet
<year>2016</year>;<volume>53</volume>:<fpage>511</fpage>–<lpage>522</lpage>.<pub-id pub-id-type="pmid">26989088</pub-id></mixed-citation>
</ref>
<ref id="R9">
<label>9.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>Rojas-Soto</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Oguni</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kennedy</surname><given-names>MB</given-names></name></person-group>
<article-title>A synaptic Ras-GTPase activating protein (p135 SynGAP) inhibited by CaM kinase II</article-title>. <source/>Neuron
<year>1998</year>;<volume>20</volume>:<fpage>895</fpage>–<lpage>904</lpage>.<pub-id pub-id-type="pmid">9620694</pub-id></mixed-citation>
</ref>
<ref id="R10">
<label>10.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Liao</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Lau</surname><given-names>LF</given-names></name>, <name name-style="western"><surname>Huganir</surname><given-names>RL</given-names></name></person-group>
<article-title>SynGAP: a synaptic RasGAP that associates with the PSD-95/SAP90 protein family</article-title>. <source/>Neuron
<year>1998</year>;<volume>20</volume>:<fpage>683</fpage>–<lpage>691</lpage>.<pub-id pub-id-type="pmid">9581761</pub-id></mixed-citation>
</ref>
<ref id="R11">
<label>11.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeyabalan</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Clement</surname><given-names>JP</given-names></name></person-group>
<article-title>SYNGAP1: mind the gap [online serial]</article-title>. <source/>Front Cell Neurosci
<year>2016</year>;<volume>10</volume>:<fpage>1</fpage>–<lpage>16</lpage>.<pub-id pub-id-type="pmid">26858601</pub-id></mixed-citation>
</ref>
<ref id="R12">
<label>12.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tidyman</surname><given-names>WE</given-names></name>, <name name-style="western"><surname>Rauen</surname><given-names>KA</given-names></name></person-group>
<article-title>Expansion of the RASopathies</article-title>. <source/>Curr Genet Med Rep
<year>2016</year>;<volume>4</volume>:<fpage>57</fpage>–<lpage>64</lpage>.<pub-id pub-id-type="pmid">27942422</pub-id></mixed-citation>
</ref>
<ref id="R13">
<label>13.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>HK</given-names></name>, <name name-style="western"><surname>Takamiya</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Huganir</surname><given-names>RL</given-names></name></person-group>
<article-title>The role of synaptic GTPase-activating protein in neuronal development and synaptic plasticity</article-title>. <source/>J Neurosci
<year>2003</year>;<volume>23</volume>:<fpage>1119</fpage>–<lpage>1124</lpage>.<pub-id pub-id-type="pmid">12598599</pub-id></mixed-citation>
</ref>
<ref id="R14">
<label>14.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Komiyama</surname><given-names>NH</given-names></name>, <name name-style="western"><surname>Watabe</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Carlisle</surname><given-names>HJ</given-names></name>, <etal>et al</etal></person-group>
<article-title>SynGAP regulates ERK/MAPK signaling, synaptic plasticity, and learning in the complex with postsynaptic density 95 and NMDA receptor</article-title>. <source/>J Neurosci
<year>2002</year>;<volume>22</volume>:<fpage>9721</fpage>–<lpage>9732</lpage>.<pub-id pub-id-type="pmid">12427827</pub-id></mixed-citation>
</ref>
<ref id="R15">
<label>15.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Hamilton</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Reish</surname><given-names>NJ</given-names></name>, <name name-style="western"><surname>Sweatt</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Miller</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Rumbaugh</surname><given-names>G</given-names></name></person-group>
<article-title>Reduced expression of the NMDA receptor-interacting protein SynGAP causes behavioral abnormalities that model symptoms of schizophrenia</article-title>. <source/>Neuropsychopharmacology
<year>2009</year>;<volume>34</volume>:<fpage>1659</fpage>–<lpage>1672</lpage>.<pub-id pub-id-type="pmid">19145222</pub-id></mixed-citation>
</ref>
<ref id="R16">
<label>16.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clement</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Aceti</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Creson</surname><given-names>TK</given-names></name>, <etal>et al</etal></person-group>
<article-title>Pathogenic SYNGAP1 mutations impair cognitive development by disrupting the maturation of dendritic spine synapses</article-title>. <source/>Cell
<year>2013</year>;<volume>151</volume>:<fpage>709</fpage>–<lpage>723</lpage>.</mixed-citation>
</ref>
<ref id="R17">
<label>17.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parker</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Fryer</surname><given-names>AE</given-names></name>, <name name-style="western"><surname>Shears</surname><given-names>DJ</given-names></name>, <etal>et al</etal></person-group>
<article-title>De novo, heterozygous, loss-of-function mutations in SYNGAP1 cause a syndromic form of intellectual disability</article-title>. <source/>Am J Med Genet A
<year>2015</year>;<volume>167A</volume>:<fpage>2231</fpage>–<lpage>2237</lpage>.<pub-id pub-id-type="pmid">26079862</pub-id></mixed-citation>
</ref>
<ref id="R18">
<label>18.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vissers</surname><given-names>LE</given-names></name>, <name name-style="western"><surname>de Ligt</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Gilissen</surname><given-names>C</given-names></name>, <etal>et al</etal></person-group>
<article-title>A de novo paradigm for mental retardation</article-title>. <source/>Nat Genet
<year>2010</year>;<volume>42</volume>:<fpage>1109</fpage>–<lpage>1112</lpage>.<pub-id pub-id-type="pmid">21076407</pub-id></mixed-citation>
</ref>
<ref id="R19">
<label>19.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamdan</surname><given-names>FF</given-names></name>, <name name-style="western"><surname>Gauthier</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Araki</surname><given-names>Y</given-names></name>, <etal>et al</etal></person-group>
<article-title>Excess of de novo deleterious mutations in genes associated with glutamatergic systems in nonsyndromic intellectual disability</article-title>. <source/>Am J Hum Genet
<year>2011</year>;<volume>88</volume>:<fpage>306</fpage>–<lpage>316</lpage>.<pub-id pub-id-type="pmid">21376300</pub-id></mixed-citation>
</ref>
<ref id="R20">
<label>20.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Ligt</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Willemsen</surname><given-names>MH</given-names></name>, <name name-style="western"><surname>van Bon</surname><given-names>BWM</given-names></name>, <etal>et al</etal></person-group>
<article-title>Diagnostic exome sequencing in persons with severe intellectual disability</article-title>. <source/>N Engl J Med
<year>2012</year>;<volume>367</volume>:<fpage>1921</fpage>–<lpage>1929</lpage>.<pub-id pub-id-type="pmid">23033978</pub-id></mixed-citation>
</ref>
<ref id="R21">
<label>21.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rauch</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Wieczorek</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Graf</surname><given-names>E</given-names></name>, <etal>et al</etal></person-group>
<article-title>Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: an exome sequencing study</article-title>. <source/>Lancet
<year>2012</year>;<volume>380</volume>:<fpage>1674</fpage>–<lpage>1682</lpage>.<pub-id pub-id-type="pmid">23020937</pub-id></mixed-citation>
</ref>
<ref id="R22">
<label>22.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berryer</surname><given-names>MH</given-names></name>, <name name-style="western"><surname>Hamdan</surname><given-names>FF</given-names></name>, <name name-style="western"><surname>Klitten</surname><given-names>LL</given-names></name>, <etal>et al</etal></person-group>
<article-title>Mutations in SYNGAP1 cause intellectual disability, autism, and a specific form of epilepsy by inducing haploinsufficiency</article-title>. <source/>Human Mutat
<year>2013</year>;<volume>34</volume>:<fpage>385</fpage>–<lpage>394</lpage>.</mixed-citation>
</ref>
<ref id="R23">
<label>23.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>von Stülpnagel</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Funke</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Haberl</surname><given-names>C</given-names></name>, <etal>et al</etal></person-group>
<article-title>SYNGAP1 mutation in focal and generalized epilepsy: a literature overview and a case report with special aspects of the EEG</article-title>. <source/>Neuropediatrics
<year>2015</year>;<volume>46</volume>:<fpage>287</fpage>–<lpage>291</lpage>.<pub-id pub-id-type="pmid">26110312</pub-id></mixed-citation>
</ref>
<ref id="R24">
<label>24.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Redin</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Gérard</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Lauer</surname><given-names>J</given-names></name>, <etal>et al</etal></person-group>
<article-title>Efficient strategy for the molecular diagnosis of intellectual disability using targeted high-throughput sequencing</article-title>. <source/>J Med Genet
<year>2014</year>;<volume>51</volume>:<fpage>724</fpage>–<lpage>736</lpage>.<pub-id pub-id-type="pmid">25167861</pub-id></mixed-citation>
</ref>
<ref id="R25">
<label>25.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dyment</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Tétreault</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Beaulieu</surname><given-names>CL</given-names></name>, <etal>et al</etal></person-group>
<article-title>Whole-exome sequencing broadens the phenotypic spectrum of rare pediatric epilepsy: a retrospective study</article-title>. <source/>Clin Genet
<year>2015</year>;<volume>88</volume>:<fpage>34</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="pmid">25046240</pub-id></mixed-citation>
</ref>
<ref id="R26">
<label>26.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O’Roak</surname><given-names>BJ</given-names></name>, <name name-style="western"><surname>Stessman</surname><given-names>HA</given-names></name>, <name name-style="western"><surname>Boyle</surname><given-names>EA</given-names></name>, <etal>et al</etal></person-group>
<article-title>Recurrent de novo mutations implicate novel genes underlying simplex autism risk</article-title>. <source/>Nat Commun
<year>2014</year>;<volume>5</volume>:<fpage>5595</fpage>.<pub-id pub-id-type="pmid">25418537</pub-id></mixed-citation>
</ref>
<ref id="R27">
<label>27.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prchalova</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Havlovicova</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sterbova</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Stranecky</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Hancarova</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sedlacek</surname><given-names>Z</given-names></name></person-group>
<article-title>Analysis of 31-year-old patient with SYNGAP1 gene defect points to importance of variants in broader splice regions and reveals developmental trajectory of SYNGAP1-associated phenotype: case report</article-title>. <source/>BMC Med Genet
<year>2017</year>;<volume>18</volume>:<fpage>62</fpage>.<pub-id pub-id-type="pmid">28576131</pub-id></mixed-citation>
</ref>
<ref id="R28">
<label>28.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McRae</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Clayton</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Fitzgerald</surname><given-names>TW</given-names></name>, <etal>et al</etal></person-group>
<article-title>Prevalence and architecture of de novo mutations in developmental disorders</article-title>. <source/>Nature
<year>2017</year>;<volume>542</volume>:<fpage>433</fpage>–<lpage>438</lpage>.<pub-id pub-id-type="pmid">28135719</pub-id></mixed-citation>
</ref>
<ref id="R29">
<label>29.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richards</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Aziz</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Bale</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group>
<article-title>Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology</article-title>. <source/>Genet Med
<year>2015</year>;<volume>17</volume>:<fpage>405</fpage>–<lpage>424</lpage>.<pub-id pub-id-type="pmid">25741868</pub-id></mixed-citation>
</ref>
<ref id="R30">
<label>30.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reutens</surname><given-names>TC</given-names></name>, <name name-style="western"><surname>Howell</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Gebert</surname><given-names>KE</given-names></name>, <name name-style="western"><surname>Berkovic</surname><given-names>SF</given-names></name></person-group>
<article-title>Validation of a questionnaire for clinical seizure diagnosis</article-title>. <source/>Epilepsia
<year>1992</year>;<volume>33</volume>:<fpage>1065</fpage>–<lpage>1071</lpage>.<pub-id pub-id-type="pmid">1464265</pub-id></mixed-citation>
</ref>
<ref id="R31">
<label>31.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fisher</surname><given-names>RS</given-names></name>, <name name-style="western"><surname>Cross</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>French</surname><given-names>JA</given-names></name>, <etal>et al</etal></person-group>
<article-title>Operational classification of seizure types by the International League Against Epilepsy [online serial]</article-title>. <source/>Epilepsia
<year>2017</year>:<fpage>1</fpage>–<lpage>9</lpage>. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.ilae.org">ilae.org</ext-link>. Accessed January 17, 2018.</mixed-citation>
</ref>
<ref id="R32">
<label>32.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scheffer</surname><given-names>IE</given-names></name>, <name name-style="western"><surname>Berkovic</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Capovilla</surname><given-names>G</given-names></name>, <etal>et al</etal></person-group>
<article-title>ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology [online serial]</article-title>. <source/>Epilepsia
<year>2017</year>:<fpage>1</fpage>–<lpage>10</lpage>. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.ilae.org">ilae.org</ext-link>. Accessed January 17, 2018.</mixed-citation>
</ref>
<ref id="R33">
<label>33.</label>
<mixed-citation publication-type="book"><collab>American Psychiatric Association</collab>. <source/>Diagnostic and Statistical Manual of Mental Disorders: DSM-V, <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>American Psychiatric Association</publisher-name>; <year>2013</year>.</mixed-citation>
</ref>
<ref id="R34">
<label>34.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bateman</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Martin</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>O'Donovan</surname><given-names>C</given-names></name>, <etal>et al</etal></person-group>
<article-title>UniProt: a hub for protein information</article-title>. <source/>Nucleic Acids Res
<year>2015</year>;<volume>43</volume>:<fpage>D204</fpage>–<lpage>D212</lpage>.<pub-id pub-id-type="pmid">25348405</pub-id></mixed-citation>
</ref>
<ref id="R35">
<label>35.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krawczak</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Riess</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Cooper</surname><given-names>DN</given-names></name></person-group>
<article-title>The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences</article-title>. <source/>Hum Genet
<year>1992</year>;<volume>90</volume>:<fpage>41</fpage>–<lpage>54</lpage>.<pub-id pub-id-type="pmid">1427786</pub-id></mixed-citation>
</ref>
<ref id="R36">
<label>36.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeavons</surname><given-names>PM</given-names></name></person-group>
<article-title>Nosological problems of myoclonic epilepsies in childhood and adolescence</article-title>. <source/>Dev Med Child Neurol
<year>1977</year>;<volume>19</volume>:<fpage>3</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">403103</pub-id></mixed-citation>
</ref>
<ref id="R37">
<label>37.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doose</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Gerken</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Leonhardt</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Völzke</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Völz</surname><given-names>C</given-names></name></person-group>
<article-title>Centrencephalic myoclonic-astatic petit mal: clinical and genetic investigation</article-title>. <source/>Neuropadiatrie
<year>1970</year>;<volume>2</volume>:<fpage>59</fpage>–<lpage>78</lpage>.<pub-id pub-id-type="pmid">5001125</pub-id></mixed-citation>
</ref>
<ref id="R38">
<label>38.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lek</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Karczewski</surname><given-names>KJ</given-names></name>, <name name-style="western"><surname>Minikel</surname><given-names>EV</given-names></name>, <etal>et al</etal></person-group>
<article-title>Analysis of protein-coding genetic variation in 60,706 humans</article-title>. <source/>Nature
<year>2016</year>;<volume>536</volume>:<fpage>285</fpage>–<lpage>291</lpage>.<pub-id pub-id-type="pmid">27535533</pub-id></mixed-citation>
</ref>
<ref id="R39">
<label>39.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Striano</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Capovilla</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Sofia</surname><given-names>V</given-names></name>, <etal>et al</etal></person-group>
<article-title>Eyelid myoclonia with absences (Jeavons syndrome): a well-defined idiopathic generalized epilepsy syndrome or a spectrum of photosensitive conditions?</article-title>
<source/>Epilepsia
<year>2009</year>;<volume>50</volume>:<fpage>15</fpage>–<lpage>19</lpage>.<pub-id pub-id-type="pmid">19469840</pub-id></mixed-citation>
</ref>
<ref id="R40">
<label>40.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Striano</surname><given-names>S</given-names></name></person-group>
<article-title>Eyelid myoclonia with absences: an overlooked epileptic syndrome?</article-title>
<source/>Neurophysiol Clin
<year>2002</year>;<volume>32</volume>:<fpage>287</fpage>–<lpage>296</lpage>.<pub-id pub-id-type="pmid">12490326</pub-id></mixed-citation>
</ref>
<ref id="R41">
<label>41.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caraballo</surname><given-names>RH</given-names></name>, <name name-style="western"><surname>Fontana</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Darra</surname><given-names>F</given-names></name>, <etal>et al</etal></person-group>
<article-title>A study of 63 cases with eyelid myoclonia with or without absences: type of seizure or an epileptic syndrome?</article-title>
<source/>Seizure
<year>2009</year>;<volume>18</volume>:<fpage>440</fpage>–<lpage>445</lpage>.<pub-id pub-id-type="pmid">19419888</pub-id></mixed-citation>
</ref>
<ref id="R42">
<label>42.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadleir</surname><given-names>LG</given-names></name>, <name name-style="western"><surname>Vears</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Regan</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Redshaw</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Bleasel</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Scheffer</surname><given-names>IE</given-names></name></person-group>
<article-title>Family studies of individuals with eyelid myoclonia with absences</article-title>. <source/>Epilepsia
<year>2012</year>;<volume>53</volume>:<fpage>2141</fpage>–<lpage>2148</lpage>.<pub-id pub-id-type="pmid">23205932</pub-id></mixed-citation>
</ref>
<ref id="R43">
<label>43.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fournier-Goodnight</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Gabriel</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Perry</surname><given-names>MS</given-names></name></person-group>
<article-title>Preliminary neurocognitive outcomes in Jeavons syndrome</article-title>. <source/>Epilepsy Behav
<year>2015</year>;<volume>52</volume>:<fpage>260</fpage>–<lpage>263</lpage>.<pub-id pub-id-type="pmid">26492104</pub-id></mixed-citation>
</ref>
<ref id="R44">
<label>44.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stephani</surname><given-names>U</given-names></name></person-group>
<article-title>The natural history of myoclonic astatic epilepsy (Doose syndrome) and Lennox-Gastaut syndrome</article-title>. <source/>Epilepsia
<year>2006</year>;<volume>47</volume>(<issue>suppl 2</issue>):<fpage>53</fpage>–<lpage>55</lpage>.<pub-id pub-id-type="pmid">17105462</pub-id></mixed-citation>
</ref>
<ref id="R45">
<label>45.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oguni</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Hayashi</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Awaya</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Fukuyama</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Osawa</surname><given-names>M</given-names></name></person-group>
<article-title>Severe myoclonic epilepsy in infants: a review based on the Tokyo Women's Medical University series of 84 cases</article-title>. <source/>Brain Dev
<year>2001</year>;<volume>23</volume>:<fpage>736</fpage>–<lpage>748</lpage>.<pub-id pub-id-type="pmid">11701288</pub-id></mixed-citation>
</ref>
<ref id="R46">
<label>46.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arzimanoglou</surname><given-names>A</given-names></name>, <name name-style="western"><surname>French</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Blume</surname><given-names>WT</given-names></name>, <etal>et al</etal></person-group>
<article-title>Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology</article-title>. <source/>Lancet Neurol
<year>2009</year>;<volume>8</volume>:<fpage>82</fpage>–<lpage>93</lpage>.<pub-id pub-id-type="pmid">19081517</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>